Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology
- II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
- Correspondence to Jens T Siveke, II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, München 81675, Germany;
Contributors P. Mazur: drafting of manuscript; J. Siveke: drafting, revision and final approval of manuscript.
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease despite tremendous scientific efforts. Numerous trials have failed to improve the outcome on this deadliest of all major cancers. Potential causes include a still insufficient understanding of key features of this cancer and imperfect preclinical models for identification of active agents and mechanisms of therapeutic responses and resistance. Modern genetically engineered mouse models of PDAC faithfully recapitulate the genetic and biological evolution of human PDAC, thereby providing a potentially powerful tool for addressing tumour biological issues as well as strategies for early detection and assessment of responses to therapeutic interventions. Here, the authors will discuss opportunities and challenges in the application of genetically engineered mouse models for translational approaches in pancreatic cancer and provide a non-exhaustive list of examples with already existing or future clinical relevance.
- pancreatic cancer
- mouse models
- Helicobacter pylori
- acid-related diseases
- non-ulcer dyspepsia
- genetic polymorphisms
- gastric neoplasia
- gene expression
- pancreatic cancer
- molecular carcinogenesis
Funding This work was supported by a grant from the German Federal Ministry of Education and Research (National Genomic Research Network (NGFN-Plus), 01GS08115 to JTS).
Competing interests None.
Patient consent Obtained.
Provenance and peer review Commissioned; externally peer reviewed.